EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Alicia Pérez González

Work experience

1. Employer: Spanish Agency of Medicines and Medical Devices
   - Start date: 102021
   - End date:
   - Position: Head of Service Clinical Evaluation of Vaccines
   - Activities: Clinical assessment of marketing authorization dossiers for vaccines, Scientific Advice, Clinical trial application evaluation, assessment for Spanish Public Health Authorities, Vaccine Batch Release. Assessment of vaccine MAAs by the centralized procedure during this period: Qdenga dengue vaccine (MAH Takeda GmbH) as Rapporteur and Kostaive COVID-19 vaccine (MAH Arcturus Therapeutics Europe B.V.) as Co-Rapporteur in a Multinational Team (currently under evaluation).
   - Country: Spain
2. Employer: Spanish Agency of Medicines and Medical Devices
   - Start date: 052017
   - End date: 092021
   - Position: Vaccines Head of Section
   - Activities: Clinical assessment of marketing authorization dossiers for vaccines, Scientific Advice, Clinical trial application evaluation, assessment for Spanish Public Health Authorities, Vaccine Batch Release. Assessment of vaccine MAAs by the centralized procedure during this period: Dengvaxia dengue vaccine (MAH Sanofi Pasteur) as Co-Rapporteur, Flucelvax Tetra influenza vaccine as Rapporteur and Fluad Tetra influenza vaccine as Rapporteur (MAH for both influenza vaccines is Seqirus Netherlands B.V.)
   - Country: Spain
3. Employer: Spanish Agency of Medicines and Medical Devices
   - Start date: 032012
   - End date: 042017
   - Position: Clinical Assessor for Vaccines
   - Activities: Clinical assessment of marketing authorization dossiers for vaccines, Scientific Advice, Clinical trial application evaluation, assessment for Spanish Public Health Authorities, Vaccine Batch Release.
   - Country: Spain
4. Employer: National Biotechnology Centre (Spanish Research Council)
   - Start date: 012008
   - End date: 022012
   - Position: Postdoctoral Researcher
   - Activities: Research in influenza virus infection
   - Country: Spain

Education and training

1. Subject: Universidad Autónoma de Madrid
   - Start date: 091995
   - End date: 062000
   - Qualification: Degree in Biology, Specialist in Molecular Biology and Biochemistry
   - Organisation:
   - Country: Spain
2. Subject: National Biotechnology Centre (Spanish Research Council), Universidad Autónoma de Madrid
   - Start date: 072000
   - End date: 122007
   - Qualification: PhD in Virology
   - Organisation:
   - Country: Spain

Additional information

Publications

hCLE/RTRAF_HSPC117_DDX1_FAM98B: A new cap_binding complex that activates mRNA translation
Frontiers in Physiology, section Systems Biology, 2019
Alejandra Pazo, Alicia Pérez_González, Juan Carlos Oliveros, Maite Huarte, Juan Pablo Chavez, Amelia Nieto
Manuscript ID: 400040; doi: 10.3389/fphys.2019.00092

Apoptosis, Toll_like, RIG_I_like and NOD_like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens.
Martínez I, Oliveros JC, Cuesta I, de la Barrera J, Ausina V, Casals C, de Lorenzo A, García E, García_Fojeda B, Garmendia J, González_Nicolau M, Lacoma A, Menéndez M, Moranta D, Nieto A, Ortín J, Pérez_González A, Prat C, Ramos_Sevillano E, Regueiro V, Rodriguez_Frandsen A, Solís D, Yuste J, Bengoechea JA, Melero JA.
Front Microbiol. 2017 Mar 1;8:276. doi: 10.3389/fmicb.2017.00276

hCLE/C14orf166, a cellular protein required for viral replication, is incorporated into influenza virus particles.
Rodriguez_Frandsen A, de Lucas S, Pérez_González A, Pérez_Cidoncha M, Roldan_Gomendio A, Pazo A, Marcos_Villar L, Landeras_Bueno S, Ortín J, Nieto A.
Sci Rep. 2016 Feb 11;6:20744

hCLE/C14orf166 Associates with DDX1_HSPC117_FAM98B
in a Novel Transcription_Dependent Shuttling RNATransporting
Complex
Alicia Pérez_González*1,2., Alejandra Pazo*1,2., Rosana Navajas1, Sergio Ciordia1, Ariel Rodriguez_Frandsen1,2, Amelia Nieto1,2
*These authors contributed equally to this work
PLOS ONE 2014 | Volume 9 | Issue 3 | e90957

Cellular human CLE/C14orf166 protein interacts with influenza virus polymerase and is required for viral replication.
Rodriguez A, Pérez_González A, Nieto A.
J Virol. 2011 Nov;85(22):12062_6.

Attenuated strains of influenza A viruses do not induce degradation of RNA polymerase II.
Rodriguez A, Pérez_González A, Hossain MJ, Chen LM, Rolling T, Pérez_Breña P, Donis R, Kochs G, Nieto A.
J Virol. 2009 Nov;83(21):11166_74.

Influenza virus infection causes specific degradation of the largest subunit of cellular RNA polymerase II.
Rodriguez A, Pérez_González A, Nieto A.
J Virol. 2007 May;81(10):5315_24. Epub 2007 Mar 7. Erratum in: J Virol. 2008 Apr;82(7):3811.

hCLE/CGI_99, a human protein that interacts with the influenza virus polymerase, is an mRNA transcription modulator.
Pérez_González A, Rodriguez A, Huarte M, Salanueva IJ, Nieto A.
J Mol Biol. 2006 Oct 6;362(5):887_900.

An alternative domain containing a leucine_rich sequence regulates nuclear cytoplasmic localization of protein 4.1R.
Luque CM, Pérez_Ferreiro CM, Pérez_González A, Englmeier L, Koffa MD, Correas I.
J Biol Chem. 2003 Jan 24;278(4):2686_91.

Overexpression of 4.1R Disturbs Microtubule Organization.
Pérez_Ferreiro CM, Luque CM, Peréz_González A, Sendino E, Correas I.
Cell Mol Biol Lett. 2001;6(2):225.

Projects

Memberships

Participation in scientific conferences:

- Participation representing Spain: ECDC Workshop on Vaccine schedules in Pediatric Investigation Plans, Stockholm (Sweden) December 10-11, 2013.
- Participation as attendant: International Symposium on cellular response to viral infection and search for new therapeutics. Organized by Joan March Foundation. Salamanca (Spain) March 26-27, 2014.
- Participation as attendant: Sixth International Conference organized by Influenza Vaccines for the World (IVW) in Lausanne (Switzerland) April 19-21, 2017.
- Participation as attendant: Symposium on Heterologous prime-boost vaccination, organized by One-Health Platform in Leuven, Belgium on September 29th 2017.
- Participation as speaker: ENOVA - European Network of Vaccine Adjuvants 3rd Workshop on Vaccine Adjuvants, Regulatory considerations, Belgrade (Serbia), September 23-24, 2019.
- Participation as speaker: Course on mRNA-based medicines, Menéndez Pelayo International University, Santander (Spain), June 22-23, 2023.

Other Relevant Information

During the pandemic, the spanish NITAG organized an expert group with the madate to design the Spanish COVID-19 vaccination strategy, of which I was part. This group started its meetings on September 2, 2020 and was closed on April 2022, after more than 200 meetings and more than 20 updates to the COVID-19 Vaccination Recommendation document.